Moxetumomab pasudotox

From WikiMD's WELLNESSPEDIA

Moxetumomab pasudotox is a recombinant immunotoxin used in the treatment of certain types of cancer. It is specifically designed to target and kill cancer cells expressing the CD22 antigen, which is commonly found on the surface of B-cell malignancies.

Mechanism of Action[edit]

Moxetumomab pasudotox is composed of an antibody fragment that binds to the CD22 antigen and a toxin derived from Pseudomonas exotoxin A. Upon binding to the CD22 antigen on the surface of cancer cells, the drug is internalized, and the toxin component is released inside the cell. This leads to the inhibition of protein synthesis and ultimately induces apoptosis (programmed cell death) in the targeted cancer cells.

Indications[edit]

Moxetumomab pasudotox is primarily indicated for the treatment of hairy cell leukemia (HCL) in patients who have received at least two prior systemic therapies, including treatment with a purine nucleoside analog.

Administration[edit]

The drug is administered via intravenous infusion over a period of 30 minutes. The recommended dosage and treatment schedule are determined based on the patient's body surface area and overall health condition.

Side Effects[edit]

Common side effects of moxetumomab pasudotox include:

Serious side effects may include:

Clinical Trials[edit]

Moxetumomab pasudotox has undergone several clinical trials to evaluate its efficacy and safety in patients with hairy cell leukemia and other B-cell malignancies. These trials have demonstrated significant clinical activity and manageable toxicity profiles.

Approval[edit]

The U.S. Food and Drug Administration (FDA) approved moxetumomab pasudotox in September 2018 for the treatment of adult patients with relapsed or refractory hairy cell leukemia who have received at least two prior systemic therapies.

Related Pages[edit]

Categories[edit]

Stub icon

This medical article is a stub. You can help WikiMD by expanding the page.


Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.

Retrieved from "https://wikimd.org/index.php?title=Moxetumomab_pasudotox&oldid=6525131"